Compare MXF & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXF | ENLV |
|---|---|---|
| Founded | 1981 | 2005 |
| Country | Mexico | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.5M | 249.3M |
| IPO Year | N/A | 1995 |
| Metric | MXF | ENLV |
|---|---|---|
| Price | $21.30 | $1.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 27.4K | ★ 485.5K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.77 | $0.66 |
| 52 Week High | $19.49 | $2.10 |
| Indicator | MXF | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 68.12 | 67.64 |
| Support Level | $19.76 | $0.92 |
| Resistance Level | $21.78 | $1.03 |
| Average True Range (ATR) | 0.47 | 0.07 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 74.75 | 98.55 |
Mexico Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation. The fund seeks to achieve its objective through investment in securities, primary in equity, listed on the Mexican Stock Exchange. The company's portfolio of investments consists of investments in different sectors such as auto parts, airports, building materials, chemical products, consumer products, energy, food, and other sectors. The fund provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.